Lai Shun Dittman Chung

Dr. Lai Shun Dittman Chung

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2020 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
WDWei Dai
Wei Dai
LCLai Shun Dittman Chung
Lai Shun Dittman Chung
LCLarry Ka-Yue Chow
Larry Ka-Yue Chow
VYValen Zhuoyou Yu
Valen Zhuoyou Yu
Lisa Chan LeiLisa Chan Lei
Lisa Chan Lei
MLMaria Li Lung
Maria Li Lung
Purpose: Investigation of biological mechanisms underlying genetic alterations in cancer can assist the understanding of etiology and identify the potential prognostic biomarkers. Experimental design: We performed an integrative genomic analysis for a total of 731 NPC cases from five independent NPC cohorts to identify the genetic events associated with clinical outcomes. Results: In addition to the known mutational signatures associated with aging, APOBEC and mismatch repair (MMR), a new signature for homologous recombination deficiency (BRCAness) was discovered in 64 of 216 (29.6%) cases in the discovery set including three cohorts. This signature appears more frequently in the recurrent and metastatic tumors and significantly correlated with shorter overall survival in the primary tumors. Independent prognostic value of MMR and BRCAness signatures were revealed by multivariable Cox analysis after adjustment for clinical parameters and stratification by studies. The cases with both signatures have much worse clinical outcome than those without these signatures (hazard ratio (HR)=12.4, P=0.002). This correlation was confirmed in the validation set (HR=8.9, P=0.003). The BRCAness signature is highly associated with BRCA2 pathogenic germline or somatic alterations (7.8% vs. 0%, P=0.002). Targeted sequencing results from a prospective NPC cohort (N=402) show that the cases carrying BRCA2 germline rare variants are more likely to have poor overall survival and progression-free survival. Conclusions: Our study highlights importance of defects of DNA repair machinery in NPC pathogenesis and their prognostic values for clinical implications. These signatures will be useful for patient stratification to evaluate conventional and new treatment for precision medicine in NPC.

Verified
Journal Article
Open access
PDF file
LCLai Shun Dittman Chung
Lai Shun Dittman Chung
GLGeoffrey Ho Duen Leung
Geoffrey Ho Duen Leung
SLSongran Liu
Songran Liu
SLSarah Wing Yan Lok
Sarah Wing Yan Lok
YXYing Xin
Ying Xin
WDWei Dai
Wei Dai
The management of nasopharyngeal cancer (NPC) is rapidly evolving, with immune checkpoint inhibitors emerging as a prominent treatment approach. However, drug development targeting specific molecular and cellular abnormalities in NPC has slowed. Recent advancements in artificial intelligence (AI) and bioinformatics, particularly those integrating multi-omics data, offer a more effective alternative to traditional in vitro screening methods for identifying clinically actionable targets in NPC. Through a combination of multi-omics analyses and AI-driven screening, we identified CACNA2D1 as a novel cancer-cell-specific therapeutic target in NPC. Our research indicates that exploiting Epstein–Barr virus (EBV) tethering increases H3K27 acetylation near the CACNA2D1 promoter. Analysis of clinical specimens revealed significant upregulation of CACNA2D1 at both the transcriptional and translational levels (p-value < 0.01). Functional studies demonstrated that the mouse tumour size shrank by one-third upon the depletion of CACNA2D1, and there was an 85% reduction in cancer cell growth through the blockage of enhancers, while the presence of CACNA2D1 conferred a survival advantage during NPC tumour development. These findings highlight the potential of CACNA2D1 as a promising target for therapeutic intervention in NPC.

31 March 2023
Verified
Other
Open access
WDWei Dai
Wei Dai
LCLai Shun Dittman Chung
Lai Shun Dittman Chung
LCLarry Ka-Yue Chow
Larry Ka-Yue Chow
VYValen Zhuoyou Yu
Valen Zhuoyou Yu
Lisa Chan LeiLisa Chan Lei
Lisa Chan Lei
MLMaria Li Lung
Maria Li Lung

31 March 2023
Verified
Other
Open access
WDWei Dai
Wei Dai
LCLai Shun Dittman Chung
Lai Shun Dittman Chung
LCLarry Ka-Yue Chow
Larry Ka-Yue Chow
VYValen Zhuoyou Yu
Valen Zhuoyou Yu
Lisa Chan LeiLisa Chan Lei
Lisa Chan Lei
MLMaria Li Lung
Maria Li Lung
Figure S7: Distinct host and EBV methylation in NPC cases with BRCAness signature. (A) Differential methylation between signature-positive and -negative cases measured by Illumina HumanMethylation450 array. (B) EBV methylation between signature-positive and -negative cases. Differential methylation was observed at two regions. (C) Differential methylation at EBV genome for two selected regions. (D) Ratios of LMP-1 and LMP-2A expression between signature-positive and -negative groups.

31 March 2023
Verified
Other
Open access
WDWei Dai
Wei Dai
LCLai Shun Dittman Chung
Lai Shun Dittman Chung
LCLarry Ka-Yue Chow
Larry Ka-Yue Chow
VYValen Zhuoyou Yu
Valen Zhuoyou Yu
Lisa Chan LeiLisa Chan Lei
Lisa Chan Lei
MLMaria Li Lung
Maria Li Lung
Table S1: Clinical parameters for the HK-3 cohort for targeted sequencing (N=402);Table S2: Sample size estimation and power calculation for study cohorts;Table S3: Mutational signatures and clinical parameters in primary NPC (N=178);Table S4: All the pathogenic germline and somatic alterations at BRCA2 (NM_000059) detected in NPC (N=216);Table S5: Germline and somatic alterations at the selected DNA damage and repair genes in 216 NPC cases for the genes with differential expression and SCNAs in NPC;Table S6: Germline rare variants detected at BRCA2 (NM_000059) in the HK-3 cohort (N=402);Table S7: Association of BRCA2 germline rare variants with clinical parameters in the HK-3 cohort (N=402);Table S8: Differentially methylated CpG sites between signature 3-positive and -negative cases

31 March 2023
Verified
Other
Open access
WDWei Dai
Wei Dai
LCLai Shun Dittman Chung
Lai Shun Dittman Chung
LCLarry Ka-Yue Chow
Larry Ka-Yue Chow
VYValen Zhuoyou Yu
Valen Zhuoyou Yu
Lisa Chan LeiLisa Chan Lei
Lisa Chan Lei
MLMaria Li Lung
Maria Li Lung
Figure S3: COSMIC signature contributions. Annotation of the signature is obtained from the Cosmic database (https://cancer.sanger.ac.uk/cosmic/signatures_v2).